This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
22 Jul 2011

AstraZeneca Receives FDA Approval for Blood-thinning Medicine

AstraZeneca announced the FDA has approved its blood-thinning drug Brilinta.

Pharma giant AstraZeneca said Wednesday it has received FDA approval for blood-thinning medication Brilinta, considered vital to the company's future success.

 

The FDA cleared the drug, used to reduce cardiovascular death and heart attacks in patients suffering from acute coronary syndromes, on the back of data compiled from 18,624 patients who participated in the PLATO study.

 

Brilinta's approval comes with the condition that AstraZeneca launch a risk evaluation and mitigation strategy, including an educational outreach programme to warn doctors over the use of the drug in combination with high doses of aspirin.

 

AstraZeneca chief executive claimed that the

Related News